ECSP034701A - Vacuna multivalente de polisacarido meningococal-conjugado de proteina - Google Patents

Vacuna multivalente de polisacarido meningococal-conjugado de proteina

Info

Publication number
ECSP034701A
ECSP034701A EC2003004701A ECSP034701A ECSP034701A EC SP034701 A ECSP034701 A EC SP034701A EC 2003004701 A EC2003004701 A EC 2003004701A EC SP034701 A ECSP034701 A EC SP034701A EC SP034701 A ECSP034701 A EC SP034701A
Authority
EC
Ecuador
Prior art keywords
protein
vaccine
polyacaride
meningococal
conjugated
Prior art date
Application number
EC2003004701A
Other languages
English (en)
Inventor
Robert Ryall
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23001755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP034701(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Publication of ECSP034701A publication Critical patent/ECSP034701A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención describe una vacuna combinada que ofrece una amplia protección contra la enfermedad meningolocal causada por la bacteria patogénica Neisseria meningitidis. La vacuna esta compuesta por cuatro diferentes conjugados polisacárido-proteína que están formulados como una sola dosis de vacuna. los polisacáridos capsulares purificados de serogrupos a Neisseria meningitidis A, C, W-135, y Y están químicamente activados y selectivamente unidos a una proteína portadora por medio de un enlace químico covalente que forma conjugados polisacárido-proteína capaces de producir inmunidad de larga duración para una variedad de cepas de N. meningitidis tanto en niños como en adultos.
EC2003004701A 2001-01-23 2003-07-23 Vacuna multivalente de polisacarido meningococal-conjugado de proteina ECSP034701A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26343501P 2001-01-23 2001-01-23

Publications (1)

Publication Number Publication Date
ECSP034701A true ECSP034701A (es) 2003-10-28

Family

ID=23001755

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004701A ECSP034701A (es) 2001-01-23 2003-07-23 Vacuna multivalente de polisacarido meningococal-conjugado de proteina

Country Status (38)

Country Link
US (9) US8722062B2 (es)
EP (3) EP2332581B1 (es)
JP (6) JP2005504718A (es)
KR (2) KR100947751B1 (es)
CN (1) CN100556459C (es)
AP (1) AP1897A (es)
AU (2) AU2007216743A1 (es)
BE (3) BE2012C050I2 (es)
BR (1) BRPI0206672B8 (es)
CA (1) CA2435681C (es)
CR (1) CR7035A (es)
CY (2) CY1113072T1 (es)
DK (2) DK2332581T3 (es)
EA (1) EA006947B1 (es)
EC (1) ECSP034701A (es)
ES (3) ES2388848T3 (es)
FR (3) FR12C0072I2 (es)
GE (1) GEP20053691B (es)
HR (1) HRP20030598B1 (es)
HU (2) HU230490B1 (es)
IL (3) IL157060A0 (es)
IS (1) IS6881A (es)
LT (1) LT5177B (es)
LU (1) LU92108I2 (es)
LV (1) LV13128B (es)
MX (2) MXPA03006561A (es)
NO (1) NO20033816L (es)
NZ (2) NZ602682A (es)
OA (1) OA12590A (es)
PL (1) PL226184B1 (es)
PT (2) PT2332581E (es)
RO (1) RO122761B1 (es)
SI (1) SI21352A (es)
TN (1) TNSN03041A1 (es)
UA (1) UA92579C2 (es)
WO (1) WO2002058737A2 (es)
YU (1) YU66103A (es)
ZA (1) ZA200306176B (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2435681C (en) 2001-01-23 2011-06-21 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
AU2014218428B2 (en) * 2001-06-20 2016-08-25 Glaxosmithkline Biologicals Sa Capsular polysaccharide solubilisation and combination vaccines
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
WO2004033623A2 (en) * 2002-05-16 2004-04-22 Aventis Pasteur, Inc. Animal component free meningococcal polysaccharide fermentation and seedbank development
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
BR0316271A (pt) * 2002-11-14 2005-10-11 Inst Finlay Ct De Investigacio Método para a obtenção de preparados vacinais conjugados multivalentes, composição vacinal multivalente e uso da mesma
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
NZ561879A (en) * 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
WO2005004909A2 (en) * 2003-05-07 2005-01-20 Aventis Pasteur, Inc. Method of enhanced immunogenicity to meningococcal vaccination
ES2596553T3 (es) * 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
MXPA05014171A (es) * 2003-06-23 2007-02-21 Sanofi Pasteur Inc Metodo de inmunizacion contra neisseria meningitidis serogrupos a y c.
KR101266552B1 (ko) * 2003-06-23 2013-05-23 박스터 헬쓰케어 에스.에이. 그룹 ｙ 수막염균에 대한 백신 및 그의 수막염균성 조합
ES2397923T3 (es) * 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) * 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
AU2011204789B2 (en) * 2004-04-22 2013-07-11 Glaxosmithkline Biologicals S.A. Immunising against meningococcal serogroup Y using proteins
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
RU2379052C2 (ru) * 2004-04-30 2010-01-20 Чирон С.Р.Л. Вакцинация менингококковыми конъюгатами
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
CA2577920A1 (en) * 2004-08-30 2006-03-09 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
AU2005286798A1 (en) * 2004-09-21 2006-03-30 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
EP1871411A4 (en) 2005-04-18 2010-07-21 Novartis Vaccines & Diagnostic EXPRESSION OF HEPATITIS B VIRUS SURFACE ANTIGEN FOR VACCINE MANUFACTURE
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
CN102973929B (zh) 2005-09-01 2017-04-26 诺华疫苗和诊断有限两合公司 含血清群c脑膜炎球菌的多价疫苗
US20070065462A1 (en) * 2005-09-21 2007-03-22 Ryall Robert P Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
KR101838938B1 (ko) 2006-03-17 2018-03-15 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
NZ572054A (en) * 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US8414899B2 (en) 2006-04-11 2013-04-09 Yeda Research And Development Co. Ltd. Vaccines comprising multimeric HSP60 peptide carriers
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
IN2009KN04098A (es) 2007-06-04 2015-08-28 Novartis Ag
HRP20120433T1 (en) 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
US8003112B2 (en) * 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
EP2519265B1 (en) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Polysaccharide immunogens conjugated to e. coli carrier proteins
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
EP2612148B1 (en) * 2010-09-04 2019-06-12 GlaxoSmithKline Biologicals SA Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
CN103533954B (zh) 2011-03-02 2015-09-09 诺华股份有限公司 含较低剂量的抗原和/或佐剂的联合疫苗
CN103764171B (zh) 2011-07-08 2016-08-17 诺华股份有限公司 酪氨酸连接方法
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
EP2852414B9 (en) 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningococcus serogroup x conjugate
PT2885007T (pt) * 2012-08-16 2018-12-10 Pfizer Processos e composições de glicoconjugação
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
JP2016502994A (ja) 2012-12-18 2016-02-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ジフテリア及び／又は破傷風から防御するためのコンジュゲート
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
US11883478B2 (en) * 2013-03-18 2024-01-30 Glaxosmithkline Biologicals S.A. Method of treatment
KR20160040556A (ko) 2013-07-11 2016-04-14 노파르티스 아게 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
EP3148577B1 (en) 2014-05-24 2021-01-20 Biological E Limited Novel semi-synthetic meningococcal conjugate vaccine
ES2927797T3 (es) 2014-09-26 2022-11-11 Seqirus Uk Ltd Vacunación de sujetos inmunocomprometidos
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
JP6830896B2 (ja) 2015-02-20 2021-02-17 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 溶解ガス発生流体を有するコントラスト造影剤
KR20160011136A (ko) 2015-03-25 2016-01-29 한국기계연구원 내식성이 향상된 마그네슘 합금 및 이를 이용하여 제조한 마그네슘 합금 부재의 제조방법
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
LT3397324T (lt) 2015-12-30 2022-10-25 Ascendis Pharma A/S Automatinis injektorius su kasečių laikymo sistema
KR102204927B1 (ko) 2016-07-25 2021-01-19 에스케이바이오사이언스(주) 피막 다당류-단백질 접합 백신의 품질 평가 방법
CN109890413B (zh) * 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
WO2020055788A1 (en) 2018-09-12 2020-03-19 Bayer Healthcare Llc System for conducting a fluid injection procedure
EP3632465A1 (en) 2018-10-03 2020-04-08 Sanofi Pasteur Inc. Combined immunization against meningococcal disease and human papillomavirus
US12005110B2 (en) 2019-02-14 2024-06-11 University Of Florida Research Foundation, Incorporated Honeybee commensal Snodgrassella alvi vaccine against pathogenic Neisseriaceae
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110903388B (zh) * 2019-12-03 2024-01-02 兰州生物制品研究所有限责任公司 一种将脑膜炎球菌抗血清去交叉反应的方法
MX2022007326A (es) 2019-12-17 2022-09-23 9286 3620 Quebec Inc Sistemas de suministro oral basados en la formacion in situ de coacervados de proteínas polisacáridos.
KR102610292B1 (ko) 2021-02-10 2023-12-04 에스케이바이오사이언스(주) 스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
TW202245836A (zh) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 重組ｂ型腦膜炎球菌疫苗
AU2023254751A1 (en) 2022-04-11 2024-11-21 Sanofi Pasteur Inc. Protein-saccharide conjugation with sodium cyanoborohydride
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
EP4758366A1 (en) 2023-08-09 2026-06-17 Bayer Healthcare LLC Noble gas delivery device, cartridge, and triggering system for lung functional and structural imaging

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351761A (en) 1978-05-15 1982-09-28 Research Corporation Purified antigen to test for Neisseria gonorrhoeae antibodies
US4404371A (en) 1981-01-14 1983-09-13 Battelle Memorial Institute Carboxymethylcellulose with carbonate bridges and preparation thereof
US4351762A (en) * 1981-03-10 1982-09-28 Bioresearch, Inc. Rapid, quantitative peptide synthesis using mixed anhydrides
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
EP0109350B1 (en) 1982-11-10 1991-10-16 Mitsubishi Jukogyo Kabushiki Kaisha Nickel-chromium alloy
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
EP0200249B1 (en) 1985-04-17 1988-10-19 Akzo N.V. Method of applying a road marking composition
DE3518706A1 (de) 1985-05-24 1986-11-27 Kernforschungszentrum Karlsruhe Gmbh, 7500 Karlsruhe Verfahren zur herstellung von formkoerpern mit verbesserten, isotropen eigenschaften
US4814276A (en) 1986-04-25 1989-03-21 Becton, Dickinson And Company Selective medium for growth of neisseria
AU640118B2 (en) 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
US4963534A (en) 1989-05-19 1990-10-16 Merck & Co., Inc. Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
WO1992016232A1 (en) 1991-03-12 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Polysaccharide-protein conjugates
US5314811A (en) 1992-07-13 1994-05-24 Merck & Co., Inc. Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
CZ28694A3 (en) 1991-08-16 1994-05-18 Merck & Co Inc Process for preparing capsular polysaccharide free of lipid and endotoxin
US5422427A (en) 1991-09-17 1995-06-06 The United States Of America As Represented By The United States Department Of Health And Human Services Pneumococcal fimbrial protein A
FR2682388B1 (fr) 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
JP3626996B2 (ja) * 1992-05-23 2005-03-09 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン
US5445817A (en) 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
CA2142981C (en) * 1992-08-31 2007-10-23 Joseph Y. Tai Vaccines against group c neisseria meningitidis
NZ311000A (en) 1995-06-07 1999-04-29 Smithkline Beecham Biolog Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
US20030157129A1 (en) 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
EP0833662B2 (en) 1995-06-23 2011-01-26 SmithKline Beecham Biologicals S.A. A vaccine composition comprsing a Haemophilus influenzae B polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US6248334B1 (en) 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
NZ331578A (en) 1997-01-21 2000-05-26 Pasteur Merieux Serums Vacc Polysaccharide-peptide-conjugates
US6891037B1 (en) 1997-01-24 2005-05-10 Schweiz. Serum- & Impfinstitut Bern Method for the isolation of polysaccharides
US6403306B1 (en) * 1997-04-09 2002-06-11 Emory University Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto
ES2230687T3 (es) 1997-04-24 2005-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Copulacion de proteinas nomodificadas con polisacaridos derivados de haloacilo o de dihaloacilo para la preparacion de vacunas que incluyen proteinas-polisacaridos.
PT1849860E (pt) 1997-05-28 2011-02-23 Novartis Vaccines & Diagnostic Processo de preparação de um factor imunogénico de corynebacterium diphtheriae utilizando um meio de cultura com extracto de levedura como fonte de aminoácidos e sem complexos proteicos de origem animal
EP0994723A1 (en) * 1997-06-24 2000-04-26 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
JP4435413B2 (ja) 1997-12-23 2010-03-17 バクスター・ヘルスケヤー・ソシエテ・アノニム ワクチンとしてまたは結合体ワクチンとしてタンパク質に連結して使用するための細菌莢膜多糖の抽出および単離法
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
PT1147117E (pt) 1999-02-01 2004-10-29 Eisai Co Ltd Compostos adjuvantes imunologicos
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
EP1179072A2 (en) 1999-05-19 2002-02-13 Chiron S.P.A. Combination neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
EP2292263A3 (en) 1999-12-02 2011-07-27 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for stabilizing biological molecules upon lyophilization
US6800455B2 (en) * 2000-03-31 2004-10-05 Scios Inc. Secreted factors
EP1946769B1 (en) 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B
CA2435681C (en) 2001-01-23 2011-06-21 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination

Also Published As

Publication number Publication date
FR15C0094I1 (es) 2016-01-22
LU92108I9 (es) 2019-01-15
US10143757B2 (en) 2018-12-04
BE2015C077I2 (es) 2021-02-04
US20160000928A1 (en) 2016-01-07
BRPI0206672B1 (pt) 2018-11-06
US20030068336A1 (en) 2003-04-10
TNSN03041A1 (en) 2005-12-23
EP1355673A2 (en) 2003-10-29
BRPI0206672B8 (pt) 2021-05-25
CY2012030I2 (el) 2016-08-31
AP2003002829A0 (en) 2003-09-30
LU92108I2 (fr) 2013-01-29
IL157060A (en) 2013-04-30
CR7035A (es) 2008-11-25
ES2388848T3 (es) 2012-10-19
HRP20030598A2 (en) 2005-06-30
MX341760B (es) 2016-09-02
DK2332581T3 (en) 2015-10-05
ES2544979T3 (es) 2015-09-07
JP2011140522A (ja) 2011-07-21
EA200300827A1 (ru) 2004-06-24
WO2002058737A3 (en) 2003-05-22
CA2435681C (en) 2011-06-21
KR100947757B1 (ko) 2010-03-18
KR20030084913A (ko) 2003-11-01
IL225522A0 (en) 2013-06-27
CN1610560A (zh) 2005-04-27
IL225522A (en) 2016-04-21
YU66103A (sh) 2006-05-25
JP2014043475A (ja) 2014-03-13
NZ602682A (en) 2014-05-30
DK1355673T3 (da) 2012-09-17
KR100947751B1 (ko) 2010-03-18
AU2010219288A1 (en) 2010-09-23
EP2332581A1 (en) 2011-06-15
US9173955B2 (en) 2015-11-03
JP2005504718A (ja) 2005-02-17
EP2332581B1 (en) 2015-07-01
CY1113072T1 (el) 2015-08-05
IL157060A0 (en) 2004-02-08
BR0206672A (pt) 2005-05-10
KR20090029857A (ko) 2009-03-23
AU2007216743A1 (en) 2007-10-04
NO20033816D0 (no) 2003-08-27
LV13128B (en) 2004-07-20
MXPA03006561A (es) 2004-10-15
EP1355673B1 (en) 2012-05-30
LT2003071A (en) 2004-08-25
JP2014065745A (ja) 2014-04-17
FR12C0072I1 (es) 2013-01-04
FR22C1001I2 (fr) 2025-02-07
IS6881A (is) 2003-07-22
UA92579C2 (ru) 2010-11-25
OA12590A (en) 2006-06-08
JP5795721B2 (ja) 2015-10-14
US8734813B2 (en) 2014-05-27
US20150174259A1 (en) 2015-06-25
US10617766B2 (en) 2020-04-14
HUS1600040I1 (hu) 2019-05-28
HUP0302999A3 (en) 2011-05-30
NO20033816L (no) 2003-09-11
PT1355673E (pt) 2012-08-31
US20130224241A1 (en) 2013-08-29
EP2957300A3 (en) 2016-03-30
US20140308311A1 (en) 2014-10-16
ES2892316T3 (es) 2022-02-03
EP2957300B1 (en) 2021-07-14
AP1897A (en) 2008-10-10
ZA200306176B (en) 2005-03-30
US20190060475A1 (en) 2019-02-28
EA006947B1 (ru) 2006-06-30
BE2012C050I2 (es) 2021-03-23
GEP20053691B (en) 2005-12-12
EP2957300A2 (en) 2015-12-23
US20130216571A1 (en) 2013-08-22
HUP0302999A2 (hu) 2003-12-29
PL226184B1 (pl) 2017-06-30
US8999354B2 (en) 2015-04-07
JP2014043474A (ja) 2014-03-13
RO122761B1 (ro) 2010-01-29
LT5177B (lt) 2004-11-25
CN100556459C (zh) 2009-11-04
US9844601B2 (en) 2017-12-19
US8722062B2 (en) 2014-05-13
WO2002058737A2 (en) 2002-08-01
PT2332581E (pt) 2015-10-16
US20130177588A1 (en) 2013-07-11
US20180154010A1 (en) 2018-06-07
US8741314B2 (en) 2014-06-03
FR12C0072I2 (fr) 2013-11-01
CA2435681A1 (en) 2002-08-01
NZ622900A (en) 2015-11-27
SI21352A (sl) 2004-06-30
CY2012030I1 (el) 2015-08-05
FR22C1001I1 (fr) 2022-02-18
JP2016128526A (ja) 2016-07-14
PL373710A1 (en) 2005-09-05
BE2022C502I2 (es) 2023-04-12
HU230490B1 (hu) 2016-08-29
HRP20030598B1 (hr) 2013-05-31
FR15C0094I2 (fr) 2017-05-19

Similar Documents

Publication Publication Date Title
MXPA03006561A (es) Vacuna del conjugado proteina-polisacarido meningococico, multivalente.
WO2005000345A3 (en) Immunization method against neisseria meningitidis serogroups a and c
WO2004103400A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines
CL2007003782A1 (es) Metodo para fabricar un conjugado inmunogenico que comprende polisacarido de streptococcus pneumoniae serotipo 3 enlazado en forma covalente a una proteina portadora.
AR053354A1 (es) Composicion de conjugado polisacarido neumococcico multivalente -proteina
TR201900418T4 (tr) Pnömokok polisakkarit konjugat aşısı.
MX2012009206A (es) Composicion de vacuna conjugada de polisacarido-proteina neumococica 15-valente.
EA200801368A1 (ru) Конъюгатные вакцины
MX348734B (es) Vacunacion multiple que incluye meningococcus del serogrupo c.
HRP20120433T1 (en) Meningococcal vaccine formulations
DK1755662T3 (da) Kombinerede meningokokkonjugater med fælles bærerprotein
ATE552844T1 (de) Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
BRPI0411815A (pt) vacinas contra neisseria meningitidis do tipo y e suas combinações meningocócicas
WO2006034320A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
WO2006026689A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
MX2007007790A (es) Conjugados y vacuna de proteina con polisacarido derivado meningococcal multivalente.
CY1116658T1 (el) Τρι- ή τετραδυναμο εμβολιο προϊοντος συζευξης μηνιγγοκοκκικου πολυσακχαριδιου-crm197
BR0004568A (pt) Vacina bivalente conjugada contra meningite tipos "b" e "c", e respectivo processo de obtenção